Amgen Calls For Halt To Neulasta Biosimilar Marketing

Law360, New York (October 19, 2015, 6:16 PM ET) -- Amgen Inc. asked a Florida federal court Friday to stop Canadian generics maker Apotex Inc. from marketing its biosimilar copy of the blockbuster biologic Neulasta until it complies with a federal law requiring it to give Amgen proper notice.



Amgen had sued Apotex in August over its proposed biosimilar to Neulasta, a drug that helps reduce the infection risk in people with non-bone-marrow-related cancers and low white blood cell counts as a result of chemotherapy, alleging it violated two patents.



Apotex hit back on Oct. 6...

To view the full article, register now.